The 2013 discovery of Telomerase reverse transcriptase (TERT) promoter mutations chr5,
1,295,228 C> T (C228T) and 1,295,250 C> T (C250T) in thyroid cancer represents an …

The 2013 discovery of Telomerase reverse transcriptase (TERT) promoter mutations chr5,
1,295,228 C> T (C228T) and 1,295,250 C> T (C250T) in thyroid cancer represents an …

Abstract Mutations 1 295 228 C> T and 1 295 250 C> T (termed C228T and C250T
respectively), corresponding to− 124 C> T and− 146 C> T from the translation start site in the …

Background: TERT encodes the reverse transcriptase component of telomerase, which adds
telomere repeats to chromosome ends, thus enabling cell replication. Telomerase activity is …

Synergistic effects of BRAF V600E and TERT promoter mutations on the poor clinical
outcomes in papillary thyroid cancer (PTC) have been demonstrated. The potential …

Thyroid carcinoma is the most common cancer in the endocrine system. Recent advances,
using next-generation sequencing, have shed light on the molecular pathogenesis of thyroid …

TERT promoter mutations are emerging prognostic biomarkers in multiple cancers and are
found in highly aggressive thyroid cancer. Our aim is to investigate the prognostic value of …

Given the long-term survival of most patients with thyroid cancer, it is very important to
distinguish patients who need aggressive treatment from those who do not. Conventional …

Background Reactivation of telomerase reverse transcriptase (TERT) is an important event
in cancer. Two hotspot mutations in the TERT promoter region, c.‐124C> T (C228T) and c …

Background: Distant metastases uncommonly occur in differentiated thyroid carcinoma
(DTC), but they are a frequent cause of thyroid cancer–related death. Genomic alterations in …